Research
The MD Anderson Surgical Oncology department focuses on providing exceptional patient care while conducting basic, translational and clinical research to develop the next generation of innovative approaches to the treatment and prevention of both common and rare cancers. We work to discover new ground-breaking surgical techniques, novel operating devices and methods to decrease cancer disparities and improve outcomes for patients. We have exceptional basic and translational research programs that are investigating the impact of the gut microbiome on immunotherapy response and are developing novel tumor models for drug testing and targeting angiogenesis. The aim is to translate laboratory findings into new treatment strategies to help patients live longer, healthier lives.
Laboratories
Wargo Laboratory
Jennifer Wargo, M.D., runs a translational research laboratory studying the genetics of melanoma and other cancers. The research of the Wargo Lab is focused on using genetic targeted therapy to arrest the growth of these cancers and to make them more visible to the immune system. The lab is currently developing clinical trials incorporating what she has learned in the laboratory to treat patients with cancer. As part of the Surgical Oncology department at MD Anderson Cancer Center, she has contributed to improving management for patients with skin cancer and other skin diseases.
Learn more about the Wargo Lab.
Torres Laboratory
Dr. Keila Torres' laboratory research efforts focus on malignant peripheral nerve sheath tumors (MPNST). The reason for focusing specifically on this histology are that these malignancies are incredibly aggressive, and effective systemic therapies are essentially nonexistent. The primary goal of Dr. Torres' laboratory is to understand the molecular deregulations responsible for the initiation and progression of high-grade soft-tissue sarcoma, and developing new approaches for its management and treatment. The lab has developed multiple cell line and patient-derived xenograft models of rare sarcomas for deeper study into the molecular mechanisms driving progression in these diseases.
Learn more about the Torres Lab.
Research Programs
T32 Training Program: Training of Academic Surgical Oncologists
The Surgical Oncology department has a long-standing grant to train eight academic surgical oncologists each year in cancer research under the collaborative leadership of Funda Meric-Bernstam, M.D., and Jennifer Wargo, M.D. Upon completion of their surgical oncology fellowship training, 100% of our T32 clinical/research fellows have entered academic surgical oncology positions. Research fellows in the program have recently published in high-impact journals including Nature, Cancer Cell, Cancer and Science, among others.
The fellowship provides research opportunities in a broad range of basic oncologic disciplines, in one of three training tracks: basic and translational research; quality, clinical effectiveness and outcomes; and clinical trials and biomarkers. Training is offered to eight postdoctoral M.D. or M.D. Ph.D. fellows either during a 24-month hiatus from general surgery residency training or during a three-year combined clinical/research fellowship in surgical oncology that begins after general surgery residency.
Learn more about the T32 Training Program.
Knox Family Foundation Health Disparities Research Program
A generous donation from the Knox Family has been made to the Surgical Oncology department to support the development of a research program focused on addressing cancer health disparities. Led by faculty with a broad range of experience in clinical trials, health services research, behavioral health and health policy, this program aims to improve equity in cancer prevention, care delivery and mortality. The program offers trainees with opportunities to gain experience in a variety of research methodologies while working to reduce cancer disparities on a local, regional and national scale.
Contact: Rebecca A. Snyder, M.D., M.P.H., F.A.C.S.
Clinical Research Informatics Program
The Clinical Research Informatics Program led by Heather Lyu, M.D., empowers researchers and clinicians with the best data and informatics solutions to deliver excellent care and make transformative advancements in the field of cancer surgery. Efficient data collection, management and analyses in health care are essential to improve patient outcomes, support evidence-based decision making and inform robust clinical and translational research. Key functions of the program include data integration, data extraction, enhanced data entry, and analytics.
Selected Publications
2024
Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Habib JR, Kinny-Köster B, Javed AA, Zelga P, Saadat LV, Kim RC, Gorris M, Allegrini V, Watanabe S, Sharib J, Arcerito M, Kaiser J, Lafaro KJ, Tu M, Bhandre M, Shi C, Kim MP, Correa C, Daamen LA, Oberstein PE, Schmidt CM, Hanna NN, Allen P, Loos M, Shrikhande SV, Molenaar IQ, Frigerio I, Katz MHG, Soares KC, Miao Y, Del Chiaro M, He J, Hackert T, Salvia R, Büchler MW, Castillo CF, Besselink MG, Marchegiani G, Wolfgang CL; Verona IPMN Consortium. J Clin Oncol. 2024 Sep10:JCO2302313. doi: 10.1200/JCO.23.02313. Online ahead of print. PMID: 39255450. View here.
Measurable imaging-based changes in enhancement of intrahepatic cholangio carcinoma after radiotherapy reflect physical mechanisms of response. De B, Dogra P, Zaid M, Elganainy D, Sun K, Amer AM, Wang C, Rooney MK, Chang E, Kang HC, Wang Z, Bhosale P, Odisio BC, Newhook TE,Tzeng CD, Cao HST, Chun YS, Vauthey JN, Lee SS, Kaseb A, Raghav K, Javle M, Minsky BD, Noticewala SS, Holliday EB, Smith GL, Koong AC, Das P, Cristini V, Ludmir EB, Koay EJ. medRxiv [Preprint]. 2024 Sep 12:2024.09.11.24313334.doi: 10.1101/2024.09.11.24313334. PMID: 39314943. View here.
Moderately hypofractionated, preoperative radiotherapy in patients with soft tissue sarcomas (HYPORT-STS): Updated local control, late toxicities, and patient-reported outcomes. Bishop AJ, Mitra D, Farooqi A, Swanson DM, Hempel C, Willis T, Pearlnath C, Wang WL, Ratan R, Somaiah N, Benjamin RS, Torres KE, Hunt KK, Scally CP, Keung EZ, Satcher RL, Bird JE, Lin PP, Moon BS, Lewis VO, Roland CL, Guadagnolo BA. Cancer. 2024 Aug 27. doi: 10.1002/cncr.35542. Online ahead of print. PMID: 39192597. View here.
Phase 1 trial of intraperitoneal paclitaxel in patients with gastric adenocarcinoma and carcinomatosis or positive cytology. Badgwell B, Ikoma N, Blum M, Wang X, Estrella J, Liu X, Kawedia J, Li J, Mansfield P, Ajani J. Cancer. 2024 Sep 17. doi: 10.1002/cncr.35566. Online ahead of print. PMID:39287936. View here.
Clinical Variables Influencing Outcomes in Patients with Atypical Intradermal Smooth Muscle Neoplasms (Formerly Cutaneous Leiomyosarcomas): Single-Institution Study of 95 Surgical Patients. Gingrich A, Wangsiricharoen S, Torres MB, Ravi V, Ratan R, Keung EZ, ScallyCP, Lazar AJ, Wang WL, Roland CL, Hunt KK, Yu W, Torres KE. Ann Surg Oncol. 2024 Aug 16. doi: 10.1245/s10434-024- 15528-x. Online ahead of print. PMID: 39150618. View here.
Phase I Trial of Total Neoadjuvant Therapy with Short Course Chemoradio therapy followed by Chemotherapy for Patients with Potentially Resectable Gastric Cancer. Badgwell B, Ikoma N, Murphy MB, Li J, WangX, Minsky BD, Estrella J, Mansfield P, Ajani J, Das P. Int J Radiat Oncol Biol Phys. 2024 Sep 3:S0360-3016(24)03319- 4. doi: 10.1016/j.ijrobp.2024.08.042. Online ahead of print. PMID: 39237045. View here.
Underrepresentation of Racial and Ethnic Minorities in Metastatic Colorectal Carcinoma Clinical Trials within the United States. Pu T, Gustafson A, Luberice K, Akmal SR, Li W, Hernandez JM, Blakely AM, SnyderRA, Eng OS. Ann Surg. 2024 Aug 15. doi: 10.1097/SLA.0000000000006500.Online ahead of print. PMID: 39145378. View here.
Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial. Ludmir EB, Sherry AD, FellmanBM, Liu S, Bathala T, Haymaker C, Medina-Rosales MN, Reuben A, HollidayEB, Smith GL, Noticewala SS, Nicholas S, Price TR, Martin-Paulpeter RM,Perles LA, Lee SS, Lee MS, Smaglo BG, Huey RW, Willis J, Zhao D, Cohen L,Taniguchi CM, Koay EJ, Katz MHG, Wolff RA, Das P, Pant S, Koong AC, TangC. J Clin Oncol. 2024 Aug 5:JCO2400081. doi: 10.1200/JCO.24.00081. Online ahead of print. PMID: 39102622. View here.
The Multi-Institutional Medullary Thyroid Cancer Collaborative Registry: Can a Rare Tumor Registry Accurately Represent the Real-World Patient Population? Szabo Yamashita T, Williams-Perez SM, Ehsan S, Mulder M, Kronenfeld D, Huang CY, Zhao H, Merriman K, Peterson SK, Hu MI, Zafereo M, Sosa JA, Grubbs EG. Thyroid. 2024 Jul 26. doi: 10.1089/thy.2024.0239. Online ahead of print. PMID: 38984944. View here.
Postoperative Adverse Events Following Neoadjuvant Therapy and Surgery for Borderline Resectable Pancreatic Cancer in a Phase 2 Clinical Trial (Alliance A021501). Snyder RA, Zemla TJ, Shi Q, Segovia D, Ahmad SA,O’Reilly EM, Herman JM, Katz MHG. Ann Surg Oncol. 2024 Jul 15. doi:10.1245/s10434-024-15670-6. Online ahead of print. PMID: 39008208. View here.
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision. Emens LA, Romero PJ,Anderson AC, Bruno TC, Capitini CM, Collyar D, Gulley JL, Hwu P, Posey ADJr, Silk AW, Wargo JA. J Immunother Cancer. 2024 Jun 19;12(6):e009063. doi:10.1136/jitc-2024-009063. PMID: 38901879. View here.
Postoperative Global Period Cost Reduction Using 3 Successive Risk-Stratified Pancreatectomy Clinical Pathways. Azimuddin A, Tzeng CD, Prakash LR, Bruno ML, Arvide EM, Dewhurst WL, Newhook TE, Kim MP, Ikoma N, Snyder RA, Lee JE, Perrier ND, Katz MH, Maxwell JE. J Am Coll Surg. 2024 Jan 5. doi: 10.1097/XCS.0000000000000944. Online ahead of print. PMID: 38180055. View here.
What Defines the Value of Minimally Invasive Surgery for Cancer Patients? Hirata Y, Lyu H, Smith GL, Wang XS, Tran Cao HS, Katz MHG, Ikoma N. Ann Surg Oncol. 2023 Dec 20. doi: 10.1245/s10434-023-14803-7. Online ahead of print. PMID: 38123730. View here.
Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit. Bhutiani N, Grotz TE, Concors SJ, White MG, Helmink BA, Raghav KP, Taggart MW, Beaty KA, Royal RE, Overman MJ, Matamoros A, Scally CP, Rafeeq S, Mansfield PF, Fournier KF. Ann Surg Oncol. 2024 Jan;31(1):614-621. doi: 10.1245/s10434-023-14422-2. Epub 2023 Oct 23. PMID: 37872456. View here.
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Roland CL, Nassif Haddad EF, Keung EZ, Wang WL, Lazar AJ, Lin H, Chelvanambi M, Parra ER, Wani K, Guadagnolo BA, Bishop AJ, Burton EM, Hunt KK, Torres KE, Feig BW, Scally CP, Lewis VO, Bird JE, Ratan R, Araujo D, Zarzour MA, Patel S, Benjamin R, Conley AP, Livingston JA, Ravi V, Tawbi HA, Lin PP, Moon BS, Satcher RL, Mujtaba B, Witt RG, Traweek RS, Cope B, Lazcano R, Wu CC, Zhou X, Mohammad MM, Chu RA, Zhang J, Damania A, Sahasrabhojane P, Tate T, Callahan K, Nguyen S, Ingram D, Morey R, Crosby S, Mathew G, Duncan S, Lima CF, Blay JY, Fridman WH, Shaw K, Wistuba I, Futreal A, Ajami N, Wargo JA, Somaiah N. Nat Cancer. 2024 Feb 13. doi: 10.1038/s43018-024-00726-z. Online ahead of print. PMID: 38351182. View here.
Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer. Cass SH, Tzeng CD, Prakash LR, Maxwell J, Snyder RA, Kim MP, Huey RW, Smaglo BG, Pant S, Koay EJ, Wolff RA, Lee JE, Katz MHG, Ikoma N. Ann Surg. 2024 Mar 20. doi: 10.1097/SLA.0000000000006269. Online ahead of print. PMID: 38506042. View here.
Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Mutation Profile and Disease Aggressiveness. Shirali AS, Hu MI, Chiang YJ, Graham PH, Fisher SB, Sosa JA, Perrier N, Brown S, Holla VR, Dadu R, Busaidy N, Sherman SI, Cabanillas M, Waguespack SG, Zafereo ME, Grubbs EG. J Endocr Soc. 2024 Apr 24;8(6):bvae048. doi: 10.1210/jendso/bvae048. eCollection 2024 Apr 6. PMID: 38660141. View here.
Correlation of Patient-Reported Social Determinants of Health With Census Tract Measures of Socioeconomic Disadvantage in Patients With GI Cancers in Eastern North Carolina. Hao S, Quinn AW, Iasiello JA, Lea CS, Popowicz P, Fu Y, Irish W, Parikh AA, Snyder RA. JCO Oncol Pract. 2024 May 17:OP2300703. doi: 10.1200/OP.23.00703. Online ahead of print. PMID: 38759124. View here.
2023
Effects of a Pragmatic Home-based Exercise Program Concurrent with Neoadjuvant Therapy on Physical Function of Patients with Pancreatic Cancer: The Pancfit Randomized Clinical Trial. Ngo-Huang AT, Parker NH, Xiao LC, Schadler KL, Petzel MQB,Prakash LR, Kim MP, Tzeng CD, Lee JE, Ikoma N, Wolff RA, Javle MM, Koay EJ, Pant SD,Folloder JP, Wang X, Cotto AM, Ju YR, Garg N, Wang H, Bruera ED, Basen-Engquist KM, KatzMHG. Ann Surg. 2023 Apr 7. doi: 10.1097/SLA.0000000000005878. Online ahead of print.PMID: 37026453. View here.
Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. Newhook TE, Vreeland TJ, Griffin JF, Tidwell RSS, Prakash LR, Koay EJ, Ludmir EB, SmagloBG, Pant S, Overman M, Wolff RA, Ikoma N, Maxwell J, Kim MP, Lee JE, Katz MHG, Tzeng CD.Ann Surg. 2022 Dec 26. doi: 10.1097/SLA.0000000000005184. Online ahead of print.PMID: 36649067. View here.
Parathyroidectomy for Normocalcemic Primary Hyperparathyroidism is Associated with Improved Bone Mineral Density Regardless of Postoperative Parathyroid Hormone Levels. Lui MS, Clemente-Gutierrez U, Vodopivec DM, Chang SL, Shirali AS, Huang BL, Chiang YJ, Fisher SB, Grubbs EG, GuiseTA, Graham PH, Perrier ND. World J Surg. 2023 Feb;47(2):363-370. doi: 10.1007/s00268-022-06756-x. Epub 2022 Oct 4. PMID: 36195677. View here.
Clinical Impact of Positive Surgical Margins in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Hirata Y, Agnes A, Estrella JS, Blum Murphy M, Das P, Minsky BD, Ajani JA, Badgwell BD,Mansfield P, Ikoma N. Ann Surg Oncol. 2023 Apr 27. doi: 10.1245/s10434-023-13495-3. Online ahead of print. PMID: 37106276. View here.
Survival improvement for patients with metastatic colorectal cancer over twenty years. Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A, Huey RW, Johnson B, Kee B, Lee MS, Morelli MP, Morris VK, Overman MJ, Parseghian C, Raghav K, Willis J, Wolff RA, Kawaguchi Y, Vauthey JN, Sun R, Kopetz S, Shen JP.NPJ Precis Oncol. 2023 Feb 13;7(1):16. doi: 10.1038/s41698-023-00353-4.PMID: 36781990. View here.
Communication Frameworks for Palliative Surgical Consultations: A Randomized Study of Advanced Cancer Patients. Blumenthaler AN, Robinson KA, Hodge C, Xiao L, Lilley EJ, Griffin JF, White MG, Day R, Tanco K, Bruera E, Badgwell BD. Ann Surg. 2023 Feb 21. doi: 10.1097/SLA.0000000000005823. Online ahead of print. PMID: 36806227. View here.
Short-Term and Textbook Surgical Outcomes During the Implementation of a Robotic Gastrectomy Program. Hirata Y, Agnes A, Arvide EM, Robinson KA, To C, Griffith HL, LaRose MD, Munder KM, Mansfield P, Badgwell BD, Ikoma N. J Gastrointest Surg. 2023 Mar 14. doi: 10.1007/s11605-023- 05627-7. Online ahead of print. PMID: 36917404. View here.
The Landscape of Immunotherapy for Retroperitoneal Sarcoma. Gingrich AA, Nassif EF, Roland CL, Keung EZ. Curr Oncol. 2023 Feb 9;30(2):2144-2158. doi: 10.3390/curroncol30020165. PMID: 36826126. View here.
Patient-Reported Adverse Events During Neoadjuvant Therapy in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501). Snyder RA, Dueck AC, Fruth B, Shi Q, Hubbard JM, Herman JM, O'Reilly EM, Katz MHG. Ann Surg.2023 Jun 19. doi: 10.1097/SLA.0000000000005958. Online ahead of print. PMID:37334719. View here.
Practice Pattern Variability in the Management of Regional Lymph Node Metastasis in Extremity and Trunk Soft Tissue Sarcoma: A Survey of the Society of Surgical Oncology and Musculoskeletal Tumor Society Membership. Witt RG, Voss RK, Chiang YJ, Nguyen S, Scally CP, Lin PP, Torres KE, Moon BS,Satcher RL, Hunt KK, Bird JE, Feig BW, Lewis VO, Roland CL, Keung EZ. Ann Surg Oncol. 2023Jun;30(6):3668-3676. doi: 10.1245/s10434-023-13142-x. Epub 2023 Feb 1. PMID: 36723723. View here.
The Room Where It Happens: Addressing Diversity, Equity, and Inclusion in NCTN Clinical Trial Leadership. Snyder RA, Burtness B, Cho M, Del Rivero J, Doroshow DB, Hitchcock KE, Kalyan A, KimCA, Lukovic J, Parikh AR, Sanford NN, Singh B, Shen C, Shroff RT, Vijayvergia N, Goodman KA, Kunz PL. JNatl Cancer Inst. 2023 Jun 26:djad121. doi: 10.1093/jnci/djad121. Online ahead of print. PMID:37364007. View here.
2022
Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop. Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GE, Marcocci C, Minisola S, Perrier N, Sitges-Serra A, Thakker RV, Guyatt G, Mannstadt M, Potts JT, Clarke BL, Brandi ML; International Workshop on Primary Hyperparathyroidism.J Bone Miner Res. 2022 Nov;37(11):2293-2314. doi: 10.1002/jbmr.4677. Epub 2022 Oct 17.PMID: 36245251. View here.
Clinical Trials
Study: 2020-0020
A Randomized Controlled Trial of Communication Strategies for Decision-Making in Palliative Surgical Consultations
Study: 2020-0481
A Phase Ib Trial of Preoperative Short-Course Chemoradiotherapy followed by Chemotherapy for Resectable Gastric Adenocarcinoma
NIH link: NCT04523818
Study: 2019-0784
A Phase I study of intraperitoneal paclitaxel in patients with gastric adenocarcinoma and carcinomatosis or positive cytology
NIH link: NCT04220827
Study: 2023-0331
A Phase II Study of Perioperative Paclitaxel in Patients with Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
Study: 2015-1133
Randomized Controlled Phase II Trial of Liver Resection Versus No Surgery in Patients with Liver and Unresectable Pulmonary Metastases from Colorectal Cancer
NIH link: NCT02738606
Study: 2020-0875
Stability of Radiomic Features for Abdominal Tumors on Contrast CT
NIH link: NCT03038568
Study: 2021-0793
Development of the Thyroid Cancer Quality of Life Index (TCQOLI)
Study: 2012-1050
A Randomized Crossover Trial of Systemic Chemotherapy in Patients with Metastatic Well-differentiated or Moderately differentiated Mucinous Appendiceal Adenocarcinomas with Pseudomyxoma Peritonei
NIH link: NCT01946854
Study: 2022-0545
Melanoma Margins Trial (MelMarT): A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for
primary cutaneous melanoma
NIH link: NCT02385214
Study: 2022-0627
Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma
NIH link: NCT03757689
Study: 2011-1090
Re-contacting Patients with Updated Genetic Testing Recommendations: A Study of Efficacy and Patient Opinions in a Cohort of High Risk Pheochromocytoma and Paraganglioma Patients
Study: 2018-0557
Designing A Decision Aid To Help People With Medullary Thyroid Cancer Make Decisions With Their Doctors About Whether To Start Or Stop New Drugs, Enroll In Clinical Trials, Or Continue With Active Surveillance
NIH link: NCT03892993
Study: 2019-0769
Utilization of the natural history of medullary thyroid carcinoma to inform advanced disease management
NIH link: NCT04216732
Study: 2021-0410
Magnetic Sentinel Lymph Node Mapping in Gastric Cancer, Safety and Feasibility Clinical Trial
NIH link: NCT05038098
Study: 2021-0799
Patient-Reported Outcomes in Surgical Patients with Upper Gastrointestinal Cancers: Development and Validation of the MDASI-UGI-Surg and Longitudinal Patients’ Quality of Life
Study: 2021-1172
Contour Topographic Mapping and Stiffness Scoring of Colorectal and Gastric Tumors Using a Novel Soft Robotic System with Intelligent Tactile Skin
Study: 2021-0914
Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers
NIH link: NCT05205343
Study: 2022-0364
Financial Toxicity after Hepatobiliary and Gastric Cancer Surgery
Study: 2023-0069
Comprehensive Morphologic and Nanmechanical Assessment to Predict Treatment Response in Gastric Cancer
Study: 2020-0265
Evaluating the impact of perioperative antibiotic prophylaxis on the microbiome in patients with cutaneous malignancy
NIH link: NCT04875728
Study: 2020-0788
Pilot Study Using Fecal Microbial Transplants in Patients with Pancreatic Cancer
NIH link: NCT04975217
Study: 2022-0854
Pilot Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients with Pancreatic Cysts Undergoing Surgical Resection
NIH link: NCT05873699
Study: 2016-1111
Randomized, Unblinded, Phase III Trial of Thoracic Epidural Analgesia versus Four-Quadrant Transversus Abdominus Plane Block in Oncologic Open-Incision Liver Surgery
NIH link: NCT03214510
Study: 2018-0093
A Feasibility Study of Electronic Neurocognitive Screening Tools in Surgery
NIH link: NCT03678441
Study: 2021-0254
Hernia Prevention After Open Hepatectomy By Small Tissue Bite Fascial Closure: A Randomized Clinical Trial
NIH link: NCT04982653
Study: 2021-0584
Risk-Stratified Adjuvant Therapy: ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases
NIH link: NCT05062317
Study: 2020-0099
Survey of Extremity and Trunk Sarcoma Surgeons Regarding Surgical Management of Lymph Node Basins
NIH link: NCT04553744
Study: 2020-0854
Evaluating the impact of limited vs. intense post-operative surveillance on patient-reported outcomes in patients with soft tissue sarcoma
NIH link: NCT04751409
Study: 2023-0484
A Randomized Phase II Study of Neoadjuvant Chemotherapy followed by Surgery vs Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS-2)
NIH link: NCT04031677
Study: 2015-0793
A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
NIH link: NCT02557321
Study: 2019-0780
RESQU-SARC
NIH link: NCT04189783
Study: 2022-0610
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors - Clinical Study
NIH link: NCT05879146
Study: 2021-0710
Use of a Handheld Mass Spectrometry System for Rapid Diagnosis of Primary and Secondary Liver Tumors
Study: 2022-1003
A Single-Arm Study of Pembrolizumab with Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
Study: 2021-0521
Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients with Colorectal Liver Metastases
NIH link: NCT05195710
Study: 2020-1054
Delineating Gut Microbiome and Dietary Determinants Associated with Favorable Vaccine Response
NIH link: NCT05239403
Study: 2022-0450
Impact of High Dietary Fiber on Microbiome and Vaccine Responses
NIH link: NCT05565586